GORTEC, known as Head and Neck Radiation Oncology Group, today announced that the randomized Phase 3 NIVOPOSTOP GORTEC 2018-01 trial evaluating nivolumab, Bristol Myers Squibb's anti-PD-1 therapy, as ...

Richard Leadbetter of Digital Foundry shared an interesting opinion when it comes to his expectations for the Switch 2. In a ...

Take a look at our DFS (daily fantasy sports) guide and recommendations. We've pooled our experts years of experience to give ...

With the NHL rolling out a 10-game schedule tonight, there’s no shortage of ways to get in on the action. I’m heading the DFS ...